Labaran Waya

Sabon Maganin rigakafi mai ƙarfi akan Omicron da Bambance-bambancen Gaba

Written by edita

Codagenix Inc., wani kamfani ne na masana'antar ilimin halitta na zamani tare da dandamalin ƙirar rigakafin rigakafin da aka yi niyya don kamuwa da cuta da kansa, a yau ya sanar da bayanan lokaci na 1 na wucin gadi wanda ke nuna ƙaddamar da rigakafin ƙwayoyin ƙwayoyin cuta na antigens da aka kiyaye sosai na bambancin SARS-CoV-2 Omicron. biye da allurai biyu na maganin alurar riga kafi na ciki, CoviLiv (wanda ake kira Covi-Vac a baya). Manya masu lafiya sun nuna ƙarin martanin rigakafi na ƙwayoyin T, wanda aka danganta da sunadaran marasa ƙarfi waɗanda ke keɓaɓɓu a cikin CoviLiv azaman ƙwayar cuta mai rai, yana nuna yuwuwar kariya ta rigakafi ta bambance-bambancen damuwa.           

Bayanan da suka gabata daga gwaji na Mataki na 1 da aka gabatar a IDWeek a watan Oktoba 2021 sun nuna cewa rigakafin intranasal CoviLiv ya haifar da martani mai ƙarfi na ƙwayar cuta (IgG) da kuma haifar da rigakafi na mucosal a cikin hanci, tare da 40% na mahalarta gabatar da anti-COVID Immunoglobulin A ( IgA) antibodies. Sabbin bayanan da aka sanar a yau sun kimanta martanin rigakafin salula kafin da bayan allurar kuma sun sami hauhawar sama da ninki huɗu a cikin martani ga tafkin peptide wanda ya mamaye sunadaran SARS-CoV-2 daban-daban guda biyar, gami da amma ba'a iyakance ga karu ba. Wannan yana nuna cewa martanin ƙwayoyin T da aka haifar sun keɓance ga sunadaran da ba su da karu, waɗanda ke da kariya sosai a cikin bambance-bambancen damuwa. Wurin da aka gwada peptide ya kasance>99.2% daidai da nau'in Omicron BA.2.

Ana sa ran cikakken bayanan CoviLiv na 1 a tsakiyar 2022. Codagenix yana kan aiwatar da kammala bin diddigin wannan gwaji na Farko na Farko na Mutum (NCT1) kuma yana fara gwaji ta amfani da CoviLiv a matsayin mai kara kuzari a cikin mutanen da aka riga aka yi musu rigakafin cutar COVID-04619628 (NCT19). Ƙara koyo game da waɗannan gwaji na asibiti a clinicaltrials.gov.

"Wannan bayanan alƙawarin sun nuna cewa CoviLiv na iya ba da amsa mai ƙarfi ga Omicron da yuwuwar bambance-bambancen nan gaba ba tare da buƙatar sake sabunta nau'ikan takamaiman nau'ikan rigakafin ba, kamar yadda ya zama dole ga allurar da aka mai da hankali kan karu. A matsayin maganin rigakafi na ciki, CoviLiv yana haifar da rigakafi na mucosal, wanda ke da alaƙa da ƙananan kamuwa da cuta da yawan watsawa kuma ana gudanar da shi cikin sauƙi-mahimmin mahimmanci don magance matsalolin samun damar rigakafin a duniya, "in ji J. Robert Coleman, Ph.D., MBA. , Co-kafa kuma Babban Jami'in Gudanarwa na Codagenix. "Tsarin tsarin ilimin halittar mu na roba yana ba mu damar samar da ingantattun alluran rigakafin da za a iya amfani da su da nufin ci gaba da yaduwar kwayar cutar kwayar cuta a cikin yanayin yanayin halittarsu na zahiri, wanda ke haifar da yuwuwar rigakafin mafi inganci da aminci."

A cikin 2020, Codagenix ya shiga cikin haɓakawa da haɗin gwiwar masana'antu tare da Cibiyar Serum ta Indiya, babbar masana'antar rigakafin rigakafi ta duniya ta allurai da aka samarwa da siyarwa. Wannan haɗin gwiwar zai ba da damar Codagenix don samun damar ingantattun ƙarfin masana'antu na Cibiyar Serum da kasuwannin kasuwanci da yawa a duniya.

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...